TSE:GEN

GeneNews (GEN) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
C$0.15
C$0.15
52-Week Range
N/A
Volume
473,147 shs
Average Volume
1.48 million shs
Market Capitalization
C$25.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
GEN stock logo

About GeneNews Stock (TSE:GEN)

GeneNews Limited focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. GeneNews Limited was founded in 1998 and is headquartered in Richmond Hill, Canada.

GEN Stock News Headlines

Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!
The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"...
Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!
The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"...
Oncology Molecular Diagnostics Market by 2031
Biotech Stock Mailbag: GenVec
StageZero Life Sciences Ltd (SZLS)
See More Headlines
Receive GEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GeneNews and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
15
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$234,592.00
Book Value
C($0.06) per share

Miscellaneous

Free Float
N/A
Market Cap
C$25.49 million
Optionable
Not Optionable
Beta
N/A
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. James R. Howard-Tripp
    Exec. Chairman & CEO
  • Ms. Joanna M. Halsey Esq.
    Gen. Counsel, Chief Compliance Officer & HR Director of IDL
  • Prof. Choong-Chin Liew Ph.D.
    Co-Founder
  • Mr. Warren Whitehead (Age 67)
    Chief Accountant
  • Mr. David Suria
    Sr. Scientist

GEN Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of GeneNews own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GeneNews investors own include StorageVault Canada (SVI), American Airlines Group (AAL), Aareal Bank (ARL), Broadcom (AVGO), Aspen Technology (AZPN), British American Tobacco (BATS), Cronos Group (CRON) and Edwards Lifesciences (EW).

How do I buy shares of GeneNews?

Shares of GEN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:GEN) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners